β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men

International Urology and Nephrology

Volumn 45, Issue 1, 2013, Pages 53-60

  Otsuki, Hideo ^a   Kosaka, Takeo ^a,b   Nakamura, Kenzo ^a   Mishima, Junnji ^c   Kuwahara, Yoshitaka ^a   Tsukamoto, Takuji ^a  

^a Nagakubo Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Mishima Hinyokika Clinic   (Japan)

Author keywords

3 Adrenoceptor; Antimuscarinics; Male OAB; Mirabegron; Overactive bladder

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; IMIDAFENACIN; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPIVERINE; SOLIFENACIN; TOLTERODINE;

AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DISEASE ASSOCIATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSURIA; ERECTILE DYSFUNCTION; FEMALE; HEART PALPITATION; HEMIPARESIS; HUMAN; INSOMNIA; INTERNATIONAL PROSTATE SYMPTOM SCORE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; OVERACTIVE BLADDER SYMPTOM SCORE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VERTIGO; XEROSTOMIA;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; AGED; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THIAZOLES; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84873408568     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0343-5     Document Type: Article

References (14)

1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG (2000) Overactive bladder significantly affects quality of life. Am J Manag Care 6:S580-S590
2. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R (2008) Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 14:291-301
3. Benner JS, Nichol MB, Rovner ES et al (2010) Patientreported reasons for discontinuing overactive bladder medication. BJU Int 105:1276-1282
4. Wein AJ, Andersson KE (2007) Pharmacologic management of storage and emptying failure. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh Urology, 9th edn. Saunders Elsevier, Philadelphia, pp 2093-2094
5. Igawa Y, Yamazaki Y, Takeda H et al (1999) Functional and molecular biological evidence. Br J Pharmacol 126:819-825
6. Takeda M, Obara K (1999) Evidence for beta3-adrenoreceptor subtypes. J Pharmacol Exp Ther 288:1367-1373
7. Yamaguchi O (2002) Beta3-adrenreceptor in human. Urology 59(5 Suppl 1):25-29
8. Fujimura T, Tamura K (1999) Expression and possible functional role of beta3-adrenoceptor in human and rat detrusor muscle. J Urol 161:680-685
9. Woods M, Carson N(2001) Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 166:1142-1147
10. Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4- yl)-40-{2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647
11. Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C (2012) Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the b(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int 110(2 Pt 2):E132-E142. doi:10.1111/j.1464- 410X.2012.11240.x
12. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M, Nishizawa O (2006) Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 68:318-323
13. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817-820
14. Astellas, Betanis (mirabegron) package insert version 3, March 2012. PMDA. http://www.info.pmda.go.jp/down files/ph/PDF/80126-2590014F1021-1-02.pdf. Accessed 10 Aug 2012